MULTIPLE SCLEROSIS
![Foto de MULTIPLE SCLEROSIS](/img/grupo.png)
![Foto de Hospital Universitario de Donostia](/img/noimage_org.png)
Hospital Universitario de Donostia
San Sebastián, EspañaPublications in collaboration with researchers from Hospital Universitario de Donostia (120)
2024
-
Bacteria–Fungi Interactions in Multiple Sclerosis
Microorganisms, Vol. 12, Núm. 5
-
Clinical characteristics and impact on patient-reported outcomes and quality of life of people with ambulatory secondary progressive multiple sclerosis: Discover study
Multiple Sclerosis and Related Disorders, Vol. 90
-
Corrigendum to “Recommendations for the use of anti-dsDNA autoantibodies in the diagnosis and follow-up of systemic lupus erythematosus – A proposal from an expert panel” [Autoimmunity Reviews, Volume 22, Issue 12, December 2023, 103479] (Autoimmunity Reviews (2023) 22(12), (S1568997223002136), (10.1016/j.autrev.2023.103479))
Autoimmunity Reviews
-
Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies
Journal of neurology, Vol. 271, Núm. 1, pp. 472-485
-
Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis
Journal of Neurology, Neurosurgery and Psychiatry, Vol. 95, Núm. 5, pp. 410-418
2023
-
Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis
JAMA Neurology, Vol. 80, Núm. 7, pp. 702-713
-
Comparative effectiveness in multiple sclerosis: A methodological comparison
Multiple Sclerosis Journal, Vol. 29, Núm. 3, pp. 326-332
-
Detecting disability using self-reported and clinical assessments in early-stage relapsing-remitting multiple sclerosis: Looking for a complementary approach
Multiple Sclerosis Journal - Experimental, Translational and Clinical, Vol. 9, Núm. 2
-
Disability accrual in primary and secondary progressive multiple sclerosis
Journal of Neurology, Neurosurgery and Psychiatry, Vol. 94, Núm. 9, pp. 707-717
-
Dysautonomia and small fiber neuropathy in post-COVID condition and Chronic Fatigue Syndrome
Journal of Translational Medicine, Vol. 21, Núm. 1
-
Early biochemical analysis of COVID-19 patients helps severity prediction
PLoS ONE, Vol. 18, Núm. 5 May
-
Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis
Multiple sclerosis (Houndmills, Basingstoke, England), Vol. 29, Núm. 7, pp. 875-883
-
Effectiveness and Safety of Teriflunomide in Relapsing–Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study
Neurology and Therapy, Vol. 12, Núm. 6, pp. 2177-2193
-
Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial
Journal of neurology, neurosurgery, and psychiatry, Vol. 94, Núm. 12, pp. 1004-1011
-
Hopelessness in Patients with Early-Stage Relapsing-Remitting Multiple Sclerosis
Patient Preference and Adherence, Vol. 17, pp. 1431-1439
-
Immune cell population and cytokine profiling suggest age dependent differences in the response to SARS-CoV-2 infection
Frontiers in Aging, Vol. 4
-
In-depth blood immune profiling of Good syndrome patients
Frontiers in Immunology, Vol. 14
-
Laboratory and clinical practices in antinuclear antibody detection and related antigens: recommendations from a Spanish multicentre survey
Immunologic Research, Vol. 71, Núm. 5, pp. 749-759
-
Recommendations for the use of anti-dsDNA autoantibodies in the diagnosis and follow-up of systemic lupus erythematosus – A proposal from an expert panel
Autoimmunity Reviews, Vol. 22, Núm. 12
-
The risk of secondary progressive multiple sclerosis is geographically determined but modifiable
Brain : a journal of neurology, Vol. 146, Núm. 11, pp. 4633-4644